secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annovis Bio, Inc. (ANVS)
CIK:        0001477845
Form:       8-K
Filed at:   2024-07-02T23:59:59+00:00
Accession:  0001104659-24-077093
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Buntanetap shows dose-dependent cognition gains; MDS-UPDRS improvements in PD Phase III
--------------------------------------------------------------------------------

- Buntanetap at 20mg significantly improved MDS-UPDRS Part II, III, II+III, and Total in PD patients diagnosed >3 years.
- In patients with mild dementia (MMSE 20-26), 20mg buntanetap showed significant cognitive improvement vs placebo.
- PIGD subgroup also showed significant motor and non-motor improvements with buntanetap.
- Safety profile consistent with prior AD data; no significant differences between early/advanced PD.
- FDA feedback led to primary endpoint change; primary and secondary endpoints met in specified subgroups.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1477845/000110465924077093/0001104659-24-077093-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1477845/000110465924077093/tm2418712d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-077093

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer